Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Rheumatoid Arthritis Drugs Market Evolve in Terms of Growth and Size by 2029?

In recent times, there has been a slight reduction in the size of the rheumatoid arthritis medicine industry. It is projected to expand from “$60.3 billion in 2024 to $60.1 billion in 2025, achieving a compound annual growth rate (CAGR) of -0.3%. The growth during the historic period is credited to factors like a rise in disease prevalence, development in healthcare infrastructure, initiatives for awareness and education, support and initiatives from the government, and strategic alliances.

The market for rheumatoid arthritis drugs is predicted to experience consistent expansion in the coming years, reaching a value of $65.34 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 2.1%. The anticipated growth within this period can be credited to trends in personalized medicine, the development of emerging markets, advancements in pipeline, a focus on combination therapies, and an increase in healthcare spending. A few key trends for the forecast period comprises dominance of biological therapies, influence of biosimilars, progress in personalized medicine, growth in oral therapies and an emphasis on early diagnosis and intervention.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10120&type=smp

What factors are expected to fuel Rheumatoid Arthritis Drugs market growth in the coming years?

The surge in arthritis cases is projected to fuel the expansion of the rheumatoid arthritis drugs market in the future. Rheumatoid arthritis, an autoimmune and inflammatory disorder, occurs when the immune system mistakenly attacks healthy cells in the body, resulting in inflammation or painful swelling in the affected areas. There are numerous drugs and self-management methods for effectively treating Rheumatoid arthritis. These drugs alleviate pain, improve joint mobility, and prevent the progression of the disease. For instance, statistics from the US-based governmental agency, National Center for Health Statistics, revealed in February 2024 that the age-adjusted prevalence of diagnosed arthritis among adults stood at 18.9% in 2022. It was found to affect women (21.5%) more than men (16.1%). The prevalence increased significantly with age, soaring from 3.6% among adults aged 18–34 to 53.9% in those aged 75 and older. Hence, the increasing incidence of arthritis is anticipated to stimulate the growth of the rheumatoid arthritis drug market.

The rheumatoid arthritis drugs market covered in this report is segmented –

1) By Drug Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Response Modifiers (BRMs), Other Drug Types

2) By Route Of Administration: Oral, Parenteral, Topical, Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Naproxen, Diclofenac, Indomethacin

2) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone

3) By Disease-Modifying Antirheumatic Drugs: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide

4) By Biologic Response Modifiers: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, B-cell Inhibitors

5) By Other Drug Types: Janus Kinase Inhibitors, Other Novel Therapies

How Are Key Trends Driving Expansion In The Rheumatoid Arthritis Drugs Industry?

A major trend sweeping across the rheumatoid arthritis drug market is the increase in product innovations. New product launches are a strategy employed by firms within this market to uphold their standing. For instance, Olokizumab, a humanized monoclonal antibody designed to target the cytokine interleukin-6, was introduced to the market by R-Pharm, a high-tech pharmaceutical company from Russia, in August 2022. This cytokine plays a vital role in accelerating joint damage in rheumatoid arthritis cases and, similar to TNF (tumor necrosis factor), causes inflammatory reactions in the body, thereby lowering disease activity for numerous rheumatoid arthritis sufferers.

What Are The Most Active Companies In The Rheumatoid Arthritis Drugs Market Today?

Major companies operating in the rheumatoid arthritis drugs market include Pfizer Inc., Abbvie Inc., Amgen Inc., Novartis AG, Boehringer Ingelheim International GmbH, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Merck & Co Inc., Johnson & Johnson Inc., Bayer AG, Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Biogen Inc., Regeneron Pharmaceuticals Inc., Galapagos NV, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Astellas Pharma Inc., Corbus Pharmaceuticals Holdings Inc., Roche Holding AG, Daiichi Sankyo Company Limited, Mallinckrodt Pharmaceuticals, Gilead Sciences Inc.

https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report

Which Regional Markets Are Attracting The Most Investment In Rheumatoid Arthritis Drugs?

North America was the largest region in the rheumatoid arthritis drugs market in 2024.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10120&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model